CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

Context for CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) trades around US$49.51, with recent returns ranging from a 1 day gain of about 1.4% to a past month decline of roughly 13.6% and a past ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.